Summary & Overview
HCPCS J3486: Injection, Ziprasidone Mesylate, 10 mg
HCPCS Level II code J3486 denotes the injectable antipsychotic ziprasidone mesylate, 10 mg. This code is used to bill for administration of the 10 mg injectable preparation of ziprasidone in facility and ambulatory settings. Nationally, injectable antipsychotics are important for acute behavioral health management, emergency psychiatric care, and inpatient treatment when oral administration is not feasible or rapid control of symptoms is required.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for injectable ziprasidone, typical sites of service where the product is administered, common billing modifiers applicable to HCPCS medication codes, and guidance on documentation elements generally expected for injectable antipsychotic claims. The publication summarizes reimbursement benchmarks where available, highlights coding specifics tied to HCPCS Level II reporting, and outlines policy considerations relevant to payer coverage and prior authorization practices.
Data not available in the input is noted where payer-specific rates, associated taxonomies, and ICD-10 diagnosis pairings would normally appear.
Billing Code Overview
HCPCS Level II code J3486 represents an injection formulation of ziprasidone mesylate, 10 mg. This billing code is used to report administration of the antipsychotic medication ziprasidone in injectable form.
Service type: Medication administration via injection
Typical site of service: Hospital inpatient, emergency department, outpatient clinic, or other facility settings where injectable antipsychotic medications are administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an emergency department or inpatient psychiatric unit with acute agitation, psychomotor agitation, or an acute exacerbation of schizophrenia or bipolar disorder with agitation requiring rapid intramuscular antipsychotic therapy. The clinician documents that oral administration is not feasible due to patient refusal, severe agitation, or risk of harm. The treatment team obtains informed consent when possible, evaluates vital signs and cardiac history (including QTc risk), and administers J3486 (injection, ziprasidone mesylate, 10 mg) intramuscularly per facility protocol. Observation for sedation, extrapyramidal symptoms, orthostatic changes, and cardiac arrhythmia occurs for the recommended monitoring period. Subsequent doses, de-escalation strategies, and transition to oral antipsychotic therapy are documented in the medical record. Typical sites of service include the emergency department, inpatient psychiatric unit, medical inpatient ward, or observation unit.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or Biological Amount Discarded/Not Administered | Use when partial vial is discarded after administering J3486 and payer requires reporting of discarded drug. |